EGFR and non-small cell lung carcinoma: In essence, VAV3.1 exemplifies how chromatin accessibility primes de novo transcriptional programs and implicates isoform switching as a bona fide resistance mechanism in EGFR-TKI-resistant NSCLC or multi-drug resistance [56].